In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique

@inproceedings{Nhama2014InVE,
  title={In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique},
  author={Abel Nhama and Quique Bassat and S{\'o}nia M Enosse and Ars{\'e}nio Nhacolo and Ros{\'a}lia Mutemba and Eva Carvalho and Eva Naueia and Esperança Sevene and Caterina Guinovart and Marian Warsame and Sergi Sanz and Abdul H Mussa and Graça Matsinhe and Pedro Alonso and Armindo Tiago and Eus{\'e}bio V Macete},
  booktitle={Malaria Journal},
  year={2014}
}
BackgroundMozambique adopted artemisinin-based combination therapy (ACT) for the treatment of uncomplicated Plasmodium falciparum malaria in the year 2006, and since 2009 artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) have been proposed as alternative first-line treatments. A multicentre study was conducted in five sites across the country to assess the in vivo efficacy and tolerability of these two drugs.MethodsChildren aged six to 59 months with uncomplicated malaria were… CONTINUE READING
4
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Evidence of artemisinin-resistant malaria in western Cambodia.

  • The New England journal of medicine
  • 2008
VIEW 1 EXCERPT